(0.90%) 5 127.75 points
(0.23%) 38 375 points
(1.15%) 17 770 points
(0.55%) $84.03
(-2.08%) $1.604
(0.44%) $2 352.70
(1.20%) $27.68
(1.30%) $932.50
(0.02%) $0.932
(-0.01%) $10.95
(-0.01%) $0.799
(-0.09%) $92.09
5 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 10.01%
@ $44.86
Issued: 25 Apr 2024 @ 10:28
Return: -1.47%
Previous signal: Apr 23 - 13:16
Previous signal:
Return: -1.21 %
Live Chart Being Loaded With Signals
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer...
Stats | |
---|---|
Today's Volume | 977 944 |
Average Volume | 1.13M |
Market Cap | 3.26B |
EPS | $0 ( 2024-02-27 ) |
Next earnings date | ( $-1.190 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.58 |
ATR14 | $3.45 (7.80%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Ashar Bhavesh | Sell | 1 824 | Common Stock |
2024-02-16 | Pichl Daniel | Buy | 15 000 | Common Stock |
2024-02-16 | Pichl Daniel | Sell | 15 000 | Common Stock |
2024-02-16 | Pichl Daniel | Sell | 15 000 | Stock Option (Right to Buy) |
2024-02-02 | Ashar Bhavesh | Sell | 1 089 | Common Stock |
INSIDER POWER |
---|
25.89 |
Last 99 transactions |
Buy: 2 487 277 | Sell: 1 935 911 |
Volume Correlation
Springworks Therapeutics Correlation
10 Most Positive Correlations | |
---|---|
NVCN | 0.932 |
PAE | 0.92 |
SY | 0.918 |
CLBT | 0.916 |
SCR | 0.914 |
CMPO | 0.914 |
ALGM | 0.911 |
PPTA | 0.91 |
EYEN | 0.907 |
PUCK | 0.907 |
10 Most Negative Correlations | |
---|---|
TUEM | -0.915 |
NAKD | -0.9 |
CYTO | -0.897 |
PROC | -0.895 |
AHPI | -0.894 |
PCSA | -0.89 |
LCAP | -0.883 |
MTEX | -0.874 |
TRIT | -0.874 |
VIEW | -0.872 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Springworks Therapeutics Correlation - Currency/Commodity
Springworks Therapeutics Financials
Annual | 2023 |
Revenue: | $5.45M |
Gross Profit: | $5.03M (92.25 %) |
EPS: | $-5.15 |
Q4 | 2023 |
Revenue: | $5.45M |
Gross Profit: | $4.49M (82.38 %) |
EPS: | $-1.280 |
Q3 | 2023 |
Revenue: | $5.59M |
Gross Profit: | $4.65M (83.30 %) |
EPS: | $-1.270 |
Q2 | 2023 |
Revenue: | $5.83M |
Gross Profit: | $5.00M (85.71 %) |
EPS: | $-1.250 |
Financial Reports:
No articles found.
Springworks Therapeutics
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators